Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
Three Arch Partners LP
In late 1993, Stanford University cardiovascular surgeon, surgery professor and physician-entrepreneur guru, Thomas Fogarty, MD, co-founded the medical device-focused venture capital firm Three Arch Partner, to go along with his clinical practice and his medical device design shop.
More from Strategy
• By
The new ESC and EACTS guidelines allow aortic stenosis patients without symptoms to be considered for a transcatheter aortic valve replacement. The move opens the market for Edwards Lifesciences, the only medtech with a Europe and US-approved device for asymptomatic severe aortic stenosis.
• By
Medtech Insight spoke with Sanjay Kakkar, Tensive CEO, about the firm’s breast tissue regeneration implant and its surgical benefits, including a reduced operation time of 74 minutes. He anticipates regulatory approval for Regenera in early 2027.
• By
SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.
• By
Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.
More from Business
Mendaera’s Handheld Robotic System Poised To ‘Transform Needle-Based Procedures’ Starting In Urology
• By
After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.
• By
SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.
• By
Galvanize will use its $100m Series C funding to expand commercial operations and advance Aliya PEF in oncology and RheOx in chronic bronchitis, while continuing to refine its nonthermal PEF platform, which delivers short electrical pulses to disrupt disease processes.